Zafgen Inc (NASDAQ:ZFGN) has analysts on the Bullish side this week.

June 19, 2017 - By Marry Poplack

 Zafgen Inc (NASDAQ:ZFGN) has analysts on the Bullish side this week.

Zafgen Inc (NASDAQ:ZFGN) Ratings Coverage

Among 8 analysts covering Zafgen Inc (NASDAQ:ZFGN), 2 have Buy rating, 0 Sell and 6 Hold. Therefore 25% are positive. Zafgen Inc had 17 analyst reports since August 25, 2015 according to SRatingsIntel. RBC Capital Markets maintained Zafgen Inc (NASDAQ:ZFGN) rating on Thursday, October 15. RBC Capital Markets has “Outperform” rating and $46 target. The firm has “Neutral” rating by Suntrust Robinson given on Thursday, December 3. FBR Capital maintained it with “Outperform” rating and $48 target in Thursday, October 15 report. FBR Capital downgraded Zafgen Inc (NASDAQ:ZFGN) on Wednesday, July 20 to “Mkt Perform” rating. RBC Capital Markets upgraded the shares of ZFGN in report on Thursday, January 21 to “Outperform” rating. On Friday, January 6 the stock rating was upgraded by JMP Securities to “Mkt Outperform”. On Wednesday, July 20 the stock rating was downgraded by Cowen & Co to “Market Perform”. The firm has “Buy” rating by Cowen & Co given on Tuesday, August 25. The firm has “Sector Perform” rating by RBC Capital Markets given on Wednesday, December 2. Canaccord Genuity maintained Zafgen Inc (NASDAQ:ZFGN) on Friday, November 13 with “Buy” rating. Below is a list of Zafgen Inc (NASDAQ:ZFGN) latest ratings and price target changes.

06/01/2017 Broker: JMP Securities Old Rating: Mkt Perform New Rating: Mkt Outperform Upgrade

It closed at $3.64 lastly. It is down 36.39% since June 19, 2016 and is downtrending. It has underperformed by 53.09% the S&P500.

Zafgen, Inc. is a biopharmaceutical company. The company has market cap of $98.29 million. The Firm is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. It currently has negative earnings. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

More notable recent Zafgen Inc (NASDAQ:ZFGN) news were published by: which released: “Zafgen Presents New Data Highlighting Potential of ZGN-1061 for the Treatment …” on June 10, 2017, also with their article: “Zafgen Announces Positive Topline Phase 1 Data for ZGN-1061, a Second …” published on May 04, 2017, published: “Zafgen Reports First Quarter 2017 Financial Results” on May 09, 2017. More interesting news about Zafgen Inc (NASDAQ:ZFGN) were released by: and their article: “Zafgen Initiates Multiple Ascending Dose Cohorts in Phase 1 Clinical Trial of …” published on September 20, 2016 as well as‘s news article titled: “Zafgen to Present at the JMP Securities Life Sciences Conference” with publication date: June 10, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: